Janney Montgomery Scott’s AbCellera Biologics ABCL Stock Holding History

Janney Montgomery Scott’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,043	Closed	-$46K	–	3105
2026 Q1	$46K	Buy	+13,043	New	+$46.9K	﹤0.01%	2724
2025 Q4	–	Sell	-10,543	Closed	-$53K	–	2909
2025 Q3	$53K	Hold	10,543	–	–	﹤0.01%	2832
2025 Q2	$36K	Sell	10,543 -2,500	-19%	-$6.22K	﹤0.01%	2681
2025 Q1	$29K	Buy	+13,043	New	+$37.4K	﹤0.01%	2646
2023 Q4	–	Sell	-19,064	Closed	-$88K	–	2620
2023 Q3	$88K	Buy	+19,064	New	+$116K	﹤0.01%	2489
2023 Q2	–	Sell	-10,193	Closed	-$77K	–	2628
2023 Q1	$77K	Buy	+10,193	New	+$92.6K	﹤0.01%	2393
2022 Q2	–	Sell	-53,261	Closed	-$519K	–	2310
2022 Q1	$519K	Sell	53,261 -130,436	-71%	-$1.23M	﹤0.01%	1588
2021 Q4	$2.63M	Buy	183,697 +27,524	+18%	+$418K	0.01%	848
2021 Q3	$3.13M	Buy	156,173 +92,502	+145%	+$1.64M	0.01%	763
2021 Q2	$1.4M	Buy	63,671 +49,976	+365%	+$1.38M	0.01%	1109
2021 Q1	$465K	Buy	+13,695	New	+$546K	﹤0.01%	1590

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Janney Montgomery Scott's ABCL Position: Q2 2026 in Review

Janney Montgomery Scott sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 13,043 shares — an estimated $46K sold.

Janney Montgomery Scott first reported a position in ABCL in Q1 2021 and held it in 11 quarters. The position peaked at $3.13M in Q3 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Janney Montgomery Scott reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Janney Montgomery Scott sold 13,043 AbCellera Biologics shares in Q2 2026, an estimated $46K.
Janney Montgomery Scott first reported a position in AbCellera Biologics in Q1 2021 and held it in 11 quarters.
Janney Montgomery Scott's AbCellera Biologics position peaked at $3.13M in Q3 2021.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.